Skip to main content
Clinical Trials/NCT04035356
NCT04035356
Terminated
Not Applicable

Safety and Performance of Aortic Valve Repair Using the HAART Aortic Annuloplasty Devices - A Registry Study

Biostable Science & Engineering5 sites in 1 country183 target enrollmentSeptember 22, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Aortic Valve Insufficiency
Sponsor
Biostable Science & Engineering
Enrollment
183
Locations
5
Primary Endpoint
Freedom from aortic valve reoperation
Status
Terminated
Last Updated
last year

Overview

Brief Summary

Multicenter US registry study to assess procedure success and long-term (10-year) performance of the HAART 200 and HAART 300 Aortic Annuloplasty Devices when used during aortic valve repair in a routine cardiovascular practice setting.

Detailed Description

The HAART Aortic Annuloplasty Devices are three-dimensional annuloplasty rings designed to be implanted intra-annularly in the aortic valve to correct annular dilatation and/or maintain annular geometry of the aortic valve in patients with trileaflet valve morphology (HAART 300) or bicuspid valve morphology (HAART 200) with moderate to severe aortic insufficiency who are undergoing aortic valve repair due to symptoms or as part of a repair for an aortic aneurysm. The study is a multicenter registry study enrolling both retrospective and prospective participants. Investigators are cardiothoracic surgeons specializing in surgery of the aortic valve and aorta at facilities with suitable infrastructure to support collection of the registry study data. Patients who underwent or will undergo aortic valve repair using either the HAART 300 or HAART 200 Device will be enrolled. All patients known to have received the HAART 300 or HAART 200 Device at participating centers will be contacted and offered the opportunity to enroll in this registry study. Prospective participants will have evaluations prior to surgery, intraoperatively, immediately following surgery, at discharge (or within 90 days), and at 1, 3, 5, and 10 years. In addition to the follow-up clinic visits, phone contacts are scheduled at years 2,4,6, 7, 8, and 9 to maintain participant engagement as well as to ascertain if any safety events have taken place. Retrospective participants who have already received the HAART 300 or HAART 200 Device prior to study enrollment will undergo safety assessment at the time of enrollment in the study.

Registry
clinicaltrials.gov
Start Date
September 22, 2020
End Date
July 25, 2024
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
Biostable Science & Engineering
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • The patient underwent or is undergoing aortic valve repair using either the HAART 300 or HAART 200 Aortic Annuloplasty Device in accordance with the Instructions for Use.
  • The patient has reviewed and signed the written informed consent form.
  • The patient agrees to return for all follow-up evaluations for the duration of the study.

Exclusion Criteria

  • Retrospective patient that has undergone a subsequent aortic valve replacement procedure.

Outcomes

Primary Outcomes

Freedom from aortic valve reoperation

Time Frame: 10 years

A reintervention for repair or replacement of the aortic valve will be considered failure for this outcome measure

Study Sites (5)

Loading locations...

Similar Trials